Dear Colleagues,
TWO WEEKS until #ASCO24 🌐
WE ARE READY
WE ARE OncoAlert 🚨

#OncoAlertAF
Dra. María Natalia Gandur Quiroga 🇦🇷
Alizée Camps - - Maléa 🇫🇷
Marta Perachino 🇮🇹
Kathrin Heinrich 🇩🇪
Biagio Ricciuti, MD PhD 🇺🇸
Deniz Can Guven 🇹🇷
Emre Yekedüz 🇺🇸
Hidehito HORINOUCHI 🇯🇵
Fadi Haddad, MD 🇺🇸
Dr. Iván R. González 🇲🇽…

💫🌟🚨 Countdown Alert: Just two weeks!! to go until #ASCO24 !
🌐 The OncoAlert team is all set to bring the latest in oncology from around the globe!

🇦🇷 Dra. María Natalia Gandur Quiroga
🇫🇷 Alizée Camps - - Maléa
🇮🇹 Marta Perachino
🇩🇪 Kathrin Heinrich
🇺🇸 Biagio Ricciuti, MD PhD
🇹🇷 Deniz Can Guven
🇺🇸 Emre Yekedüz…

📘Targeting KRAS in Colorectal Cancer
JCO Oncology Practice

✅A precision review

➡️KRAS inhibitors for G12C mutants
➡️Allele-specific inhibitors
➡️panKRAS and panRAS inhibitors
➡️Unique biological features of RAS-mutant CRC
✅Novel therapeutic avenues

👉doi.org/10.1200/OP.23.……

💊In oncology, we use steroids for many different indications.

💥A guide on steroid equivalence, dose reduction recommendations, treatment of adrenal insufficiency and more👇

Endocrine Society
academic.oup.com/jcem/advance-a…

KEYNOTE-057 JUST OUT on The Lancet Oncology
Investigates pembrolizumab 🧪efficacy and safety in BCG-unresponsive high-risk non-muscle-invasive #BladderCancer ineligible for or refusing radical cystectomy

✅Revealing in cohort B (papillary tumors without carcinoma in situ) a…

Cancer therapy with antibodies

An excellent review providing a comprehensive overview of therapeutic antibodies used in cancer treatment👇

OncoAlert
nature.com/articles/s4156…

👀Is W&W approach suitable for those with ncCR? Unknowns:What % of ncCRs convert to cCRs? How can we predict these patients? Average time from ncCR to cCR? How long to wait and when to act? JAMA Oncology Yakup Ergün Arndt Vogel OncoDaily Enes Erul MD doi:10.1001/jamaoncol.2024.0856

Clinical significance of combined TILs and MSI status in colorectal cancer

✅️The TIL-high group is associated with better survival independent of MSI or MSS status

💥According to these findings, MSI alone is insufficient for clinical decision making. Integration of TILs is…

An excellent review on gliomas👇

OncoAlert
nature.com/articles/s4157…

MONARCH 3: Final overall survival results

🔍mFU: 8.1 years (OS: secondary endpoint)

mOS➡️66.8 vs 53.7 mo (HR:0.8, p:0.06)

💥The absolute difference was 13.1 months but did not reach statistical significance

Annals of Oncology OncoAlert
annalsofoncology.org/article/S0923-…

Association between adjuvant endocrine therapy intake timing and DFS in patients with BC

Does the circadian rhythm affect endocrine therapy metabolism?

💥According to this study, taking tamoxifen in the evening/night is associated with better DFS

OncoAlert eBioMedicine – The Lancet Discovery Science…

Happy #NursesWeek

DESTINY-PanTumor01
Study evaluates trastuzumab deruxtecan, in patients with metastatic solid tumors harboring specific activating HER2 🧬mutations

✅Demonstrating significant anti-tumor activity and durable responses

➡️suggesting potential for broader application across various…

The safety of T-DXd with a focus on ILD and/or pneumonitis: meta‐analysis

🔍13 study, 1428 pts

>G3 TEAEs➡️52.6% (G5: 5.4%)
Discontinuation➡️14.4%

>G3 ILD➡️2.2% (G5: 0.5%)

6.4 mg/kg
ILD (all)➡️14.9%
>G3 ILD➡️3.1%

5.4 mg/kg
ILD (all)➡️8.0%
>G3 ILD➡️0.4%

OncoAlert…

The evolving treatment landscape of metastatic urothelial cancer

A great review on urothelial cancers, where the significant developments in terms of survival have occurred in recent times👇

OncoAlert Nature Reviews Urology
nature.com/articles/s4158…

Thank you very much to everyone who contributed by voting and commenting.

💥A large majority chose to treat ER-Low/HER2- BC like TNBC.

🔍ER-low BC accounts for about 2% of all breast cancers.
According to intrinsic subtype analyses, approximately 80% of ER-Low tumors are…

Targeting the EGFR signalling pathway in metastatic colorectal cancer

An excellent review👇

The Lancet Gastroenterology & Hepatology
thelancet.com/journals/langa…